Search

Your search keyword '"Heitz F"' showing total 1,051 results
Start Over Author "Heitz F"
1,051 results on '"Heitz F"'

3. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

Author

Pujade-Lauraine, E., Selle, F., Scambia, G., Asselain, B., Marmé, F., Lindemann, K., Colombo, N., Mądry, R., Glasspool, R., Vergote, I., Korach, J., Lheureux, S., Dubot, C., Oaknin, A., Zamagni, C., Heitz, F., Gladieff, L., Rubio-Pérez, M.J., Scollo, P., Blakeley, C., Shaw, B., Ray-Coquard, I., and Redondo, A.

Published
2023
Full Text
View/download PDF

5. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk

Author

Amankwah, EK, Lin, HY, Tyrer, JP, Lawrenson, K, Dennis, J, Chornokur, G, Aben, KKH, Anton-Culver, H, Antonenkova, N, Bruinsma, F, Bandera, EV, Bean, YT, Beckmann, MW, Bisogna, M, Bjorge, L, Bogdanova, N, Brinton, LA, Brooks-Wilson, A, Bunker, CH, Butzow, R, Campbell, IG, Carty, K, Chen, Z, Chen, YA, Chang-Claude, J, Cook, LS, Cramer, DW, Cunningham, JM, Cybulski, C, Dansonka-Mieszkowska, A, du Bois, A, Despierre, E, Dicks, E, Doherty, JA, Dörk, T, Dürst, M, Easton, DF, Eccles, DM, Edwards, RP, Ekici, AB, Fasching, PA, Fridley, BL, Gao, YT, Gentry-Maharaj, A, Giles, GG, Glasspool, R, Goodman, MT, Gronwald, J, Harrington, P, Harter, P, Hasmad, HN, Hein, A, Heitz, F, Hildebrandt, MAT, Hillemanns, P, Hogdall, CK, Hogdall, E, Hosono, S, Iversen, ES, Jakubowska, A, Jensen, A, Ji, BT, Karlan, BY, Jim, H, Kellar, M, Kiemeney, LA, Krakstad, C, Kjaer, SK, Kupryjanczyk, J, Lambrechts, D, Lambrechts, S, Le, ND, Lee, AW, Lele, S, Leminen, A, Lester, J, Levine, DA, Liang, D, Lim, BK, Lissowska, J, Lu, K, Lubinski, J, Lundvall, L, Massuger, LFAG, Matsuo, K, Mcguire, V, Mclaughlin, JR, Mcneish, I, Menon, U, Milne, RL, Modugno, F, Moysich, KB, Ness, RB, Nevanlinna, H, Eilber, U, Odunsi, K, Olson, SH, Orlow, I, Orsulic, S, and Weber, RP

Subjects
Epidemiology, Public Health and Health Services, Genetics
Abstract

Epithelial-mesenchymal transition (EMT) is a process whereby epithelial cells assume mesenchymal characteristics to facilitate cancer metastasis. However, EMT also contributes to the initiation and development of primary tumors. Prior studies that explored the hypothesis that EMT gene variants contribute to epithelial ovarian carcinoma (EOC) risk have been based on small sample sizes and none have sought replication in an independent population. We screened 15,816 single-nucleotide polymorphisms (SNPs) in 296 genes in a discovery phase using data from a genome-wide association study of EOC among women of European ancestry (1,947 cases and 2,009 controls) and identified 793 variants in 278 EMT-related genes that were nominally (P < 0.05) associated with invasive EOC. These SNPs were then genotyped in a larger study of 14,525 invasive-cancer patients and 23,447 controls. A P-value

Published
2015

6. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium

Author

Nagle, CM, Dixon, SC, Jensen, A, Kjaer, SK, Modugno, F, deFazio, A, Fereday, S, Hung, J, Johnatty, SE, Fasching, PA, Beckmann, MW, Lambrechts, D, Vergote, I, Van Nieuwenhuysen, E, Lambrechts, S, Risch, HA, Rossing, MA, Doherty, JA, Wicklund, KG, Chang-Claude, J, Goodman, MT, Ness, RB, Moysich, K, Heitz, F, du Bois, A, Harter, P, Schwaab, I, Matsuo, K, Hosono, S, Goode, EL, Vierkant, RA, Larson, MC, Fridley, BL, Høgdall, C, Schildkraut, JM, Weber, RP, Cramer, DW, Terry, KL, Bandera, EV, Paddock, L, Rodriguez-Rodriguez, L, Wentzensen, N, Yang, HP, Brinton, LA, Lissowska, J, Høgdall, E, Lundvall, L, Whittemore, A, McGuire, V, Sieh, W, Rothstein, J, Sutphen, R, Anton-Culver, H, Ziogas, A, Pearce, CL, Wu, AH, and Webb, PM

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prevention, Nutrition, Ovarian Cancer, Obesity, Rare Diseases, Cancer, Body Mass Index, Carcinoma, Ovarian Epithelial, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, ovarian cancer, obesity, overall survival, progression-free survival, ovarian cancer-specific survival, Australian Ovarian Cancer Study Group, Ovarian Cancer Association Consortium, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundObservational studies have reported a modest association between obesity and risk of ovarian cancer; however, whether it is also associated with survival and whether this association varies for the different histologic subtypes are not clear. We undertook an international collaborative analysis to assess the association between body mass index (BMI), assessed shortly before diagnosis, progression-free survival (PFS), ovarian cancer-specific survival and overall survival (OS) among women with invasive ovarian cancer.MethodsWe used original data from 21 studies, which included 12 390 women with ovarian carcinoma. We combined study-specific adjusted hazard ratios (HRs) using random-effects models to estimate pooled HRs (pHR). We further explored associations by histologic subtype.ResultsOverall, 6715 (54%) deaths occurred during follow-up. A significant OS disadvantage was observed for women who were obese (BMI: 30-34.9, pHR: 1.10 (95% confidence intervals (CIs): 0.99-1.23); BMI: ⩾35, pHR: 1.12 (95% CI: 1.01-1.25)). Results were similar for PFS and ovarian cancer-specific survival. In analyses stratified by histologic subtype, associations were strongest for women with low-grade serous (pHR: 1.12 per 5 kg m(-2)) and endometrioid subtypes (pHR: 1.08 per 5 kg m(-2)), and more modest for the high-grade serous (pHR: 1.04 per 5 kg m(-2)) subtype, but only the association with high-grade serous cancers was significant.ConclusionsHigher BMI is associated with adverse survival among the majority of women with ovarian cancer.

Published
2015

7. Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12

Author

Heitz, F., Harter, P., Åvall-Lundqvist, E., Reuss, A., Pautier, P., Cormio, G., Colombo, N., Reinthaller, A., Vergote, I., Poveda, A., Ottevanger, P.B., Hanker, L.C., Leminen, A., Alexandre, J., Canzler, U., Sehouli, J., Herrstedt, J., Fiane, B., Merger, M., and du Bois, A.

Published
2019
Full Text
View/download PDF

12. Dilution of molecular-pathologic gene signatures (MPG) by parameter unrelated to tumor biology (UTB) may prevent prediction of the resection status after debulking surgery in patients with advanced ovarian cancer

Author

Heitz, F, Kommoss, S, Tourani, R, Grandelis, A, Uppendahl, L, Aliferis, C, Burges, A, Wang, C, Canzler, U, Wang, J, Belau, A, Prader, S, Hanker, L, Ma, S, Ataseven, B, Hilpert, F, Schneider, S, Sehouli, J, Kimmig, R, Kurzeder, C, Schmalfeldt, B, Braicu, I, Harter, P, Dowdy, S C, Winterhoff, B JN, Pfisterer, J, and du Bois, A

Published
2019
Full Text
View/download PDF

13. Which Manifold Should be Used for Group Comparison in Diffusion Tensor Imaging?

Author

Bouchon, A., Noblet, V., Heitz, F., Lamy, J., Blanc, F., Armspach, J. -P., Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Weikum, Gerhard, Series editor, Navab, Nassir, editor, Hornegger, Joachim, editor, Wells, William M., editor, and Frangi, Alejandro, editor

Published
2015
Full Text
View/download PDF

14. 38MO Validation study of the ShallowHRDv2 assay for homologous recombination deficiency (HRD) detection in high-grade ovarian carcinomas (HGOC) in the first-line setting, from the phase III PAOLA-1/ENGOT-ov25 trial

Author

Callens, C., primary, Rodrigues, M.J., additional, Briaux, A., additional, Browaeys, E., additional, Eeckhoutte, A., additional, Pujade-Lauraine, E., additional, Renault, V., additional, Stoppa-Lyonnet, D., additional, Bieche, I., additional, Bataillon, G., additional, Heitz, F., additional, Chiara-Cecere, S., additional, Rubio Perez, M.J., additional, Berger, R., additional, Jakobi Nøttrup, T., additional, Colombo, N., additional, Vergote, I.B., additional, Ray-Coquard, I.L., additional, Stern, M-H., additional, and Popova, T., additional

Published
2023
Full Text
View/download PDF

15. 33O PRIMA/ENGOT-OV26/GOG-3012 study: Long-term conditional PFS

Author

Gonzalez Martin, A.J., primary, Pothuri, B., additional, Vergote, I.B., additional, Graybill, W., additional, Mirza, M.R., additional, McCormick, C., additional, Lorusso, D., additional, Freyer, G., additional, Backes, F., additional, Heitz, F., additional, Redondo Sanchez, A., additional, Moore, R., additional, Vulsteke, C., additional, O'Cearbhaill, R.E., additional, Malinowska, I., additional, Shtessel, L., additional, York, W., additional, and Monk, B.J., additional

Published
2023
Full Text
View/download PDF

18. Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis

Author

Labidi-Galy, S.I., primary, Rodrigues, M., additional, Sandoval, J.L., additional, Kurtz, J.E., additional, Heitz, F., additional, Mosconi, A.M., additional, Romero, I., additional, Denison, U., additional, Nagao, S., additional, Vergote, I., additional, Parma, G., additional, Nøttrup, T.J., additional, Rouleau, E., additional, Garnier, G., additional, El-Balat, A., additional, Zamagni, C., additional, Martín-Lorente, C., additional, Pujade-Lauraine, E., additional, Fiévet, A., additional, and Ray-Coquard, I.L., additional

Published
2022
Full Text
View/download PDF

19. Role of substage and histologic subtype in stage I epithelial ovarian cancer survival: a multicenter retrospective observational study

Author

Imterat, M, additional, Bizzarri, N, additional, Fruscio, R, additional, Perrone, AM, additional, Traut, A, additional, du Bois, A, additional, Rosati, A, additional, Ferrari, D, additional, De Iaco, P, additional, Ataseven, B, additional, Ergasti, R, additional, Volontè, S, additional, Tesei, M, additional, Heitz, F, additional, Perri, MT, additional, Concin, N, additional, Fanfani, F, additional, Scambia, G, additional, Fagotti, A, additional, and Harter, P, additional

Published
2022
Full Text
View/download PDF

20. Steigerung der Therapiequalität beim frühen Ovarialkarzinom: Ergebnisse der QS-Ovar

Author

Wimberger, P, additional, Pfisterer, J, additional, du Bois, A, additional, Hilpert, F, additional, Kerkmann, M, additional, Sehouli, J, additional, Mahner, S, additional, de Gregorio, N, additional, Hanker, L, additional, Heitz, F, additional, Marmé, F, additional, Wölber, L, additional, Holtmann, L, additional, Elser, G, additional, and Harter, P, additional

Published
2022
Full Text
View/download PDF

21. Rolle der Fertilitätserhaltenden Therapie bei Patientinnen mit Borderline-Tumoren des Ovars

Author

Westermann, T, additional, Heitz, F, additional, Ataseven, B, additional, Pauly, N, additional, Moubarak, M, additional, Strojna, A, additional, Kaiser, S, additional, Welz, J, additional, Imterat, M, additional, Concin, N, additional, Dagres, T, additional, Vrentas, V, additional, Traut, A, additional, Plett, H, additional, du Bois, A, additional, and Harter, P, additional

Published
2022
Full Text
View/download PDF

22. Real World Daten zu Therapie und Krankheitsverlauf von Patientinnen mit erstem Rezidiv eines Ovarialkarzinoms in Deutschland (QS Ovar der AGO Studiengruppe)

Author

Schmalfeldt, B, additional, du Bois, A, additional, Pfisterer, J, additional, Hilpert, F, additional, Kerkmann, M, additional, Sehouli, J, additional, Mahner, S, additional, de Gregorio, N, additional, Hanker, L, additional, Heitz, F, additional, Marmé, F, additional, Wölber, L, additional, Holtmann, L, additional, Krüger, A, additional, and Harter, P, additional

Published
2022
Full Text
View/download PDF

23. Maintenance Therapy with an Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO/LOGOS): study protocol of a randomized double-blinded placebo-controlled multi-center Phase III Trial

Author

McLaughlin, PMJ, additional, Klar, M, additional, Heitz, F, additional, Zwimpfer, TA, additional, Dutilh, G, additional, Vetter, M, additional, Marth, C, additional, du Bois, A, additional, Schade-Brittinger, C, additional, Reuss, A, additional, Bommer, C, additional, Kurzeder, C, additional, and Heinzelmann, V, additional

Published
2022
Full Text
View/download PDF

26. Chemotherapy-induced mutations in genes of clonal hematopoiesis increase the risk of myeloid neoplasms

Author

Heitz, F, additional, Weber-Lassalle, K, additional, Ernst, C, additional, Möllenhoff, K, additional, de Gregorio, N, additional, Hauke, J, additional, Dietrich, D, additional, Borde, J, additional, Jackisch, C, additional, Park-Simon, T-W, additional, Hanker, LC, additional, Pohl-Rescigno, E, additional, Prieske, K, additional, Kommoss, S, additional, Marme, F, additional, Stingl, JC, additional, Rita, S, additional, Harter, P, additional, and Hahnen, E, additional

Published
2022
Full Text
View/download PDF

27. Stellenwert der Rezidivoperation beim adulten Granulosazelltumor des Ovars

Author

Kaiser, S, additional, Harter, P, additional, Heitz, F, additional, Westermann, T, additional, Welz, J, additional, Schwameis, R, additional, Concin, N, additional, Imetrat, M, additional, Strojna, A, additional, Dagres, T, additional, Vrentas, V, additional, Hinrichs, J, additional, Boland, S, additional, Pauly, N, additional, Heikaus, S, additional, Moubarak, M, additional, Traut, A, additional, and Ataseven, B, additional

Published
2022
Full Text
View/download PDF

29. LIO-1: Initiale Phase 2 Erfahrung mit Lucitanib + Nivolumab bei Patientinnen mit persistierendem oder rezidiviertem Zervixkarzinom (NCT04042116; ENGOT-GYN3/AGO/LIO)

Author

Heitz, F, additional, Oaknin, A, additional, Backes, FJ, additional, Van Nieuwenhuysen, E, additional, Eskander, RN, additional, González-Martín, A, additional, Makker, V, additional, Marth, C, additional, Patel, M, additional, Penson, RT, additional, Redondo, A, additional, Pérez, MJR, additional, Hamilton, E, additional, Wimberger, P, additional, Concin, N, additional, Go, J, additional, Wride, K, additional, Lepley, D, additional, Dusek, R, additional, Cameron, T, additional, and Pignata, S, additional

Published
2022
Full Text
View/download PDF

33. Rolle der zytoreduktiven Operation bei Patientinnen, die beim ersten Rezidiv nicht operiert wurden: Eine Subanalyse der DESKTOP-III-Studie

Author

Heitz, F, additional, Sehouli, J, additional, Fotopoulou, C, additional, Meier, W, additional, Reuß, A, additional, Hillemanns, P, additional, Hasenburg, A, additional, Hilpert, F, additional, Denschlag, D, additional, Burges, A, additional, Hanker, LC, additional, Rheintaller, A, additional, Canzler, U, additional, Lampe, B, additional, Schutz, R, additional, Gropp-Meier, M, additional, du Bois, A, additional, and Harter, P, additional

Published
2022
Full Text
View/download PDF

36. Prospektive Identifizierung von Prädiktoren als Hinweis auf ein frühes Therapieversagen der Primärtherapie aus zytoreduktiver Operation und anschließender Chemotherapie bei Patientinnen mit fortgeschrittenem Ovarialkarzinom – Ergebnisse der AGO-OVAR 19/FRAGILE-Studie (NCT02828618)

Author

Trillsch, F, additional, Heitz, F, additional, Krämer, B, additional, Oerke, B, additional, Sehouli, J, additional, Lampe, B, additional, Schmaldeldt, B, additional, Wimberger, P, additional, Witteler, R, additional, Buderath, P, additional, Herwig, U, additional, Bronger, H, additional, Müller, A, additional, Reuß, A, additional, Peters, N, additional, Hanf, V, additional, du Bois, A, additional, Harter, P, additional, Mahner, S, additional, and Hilpert, F, additional

Published
2022
Full Text
View/download PDF

38. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

Author

Dareng, EO, Tyrer, JP, Barnes, DR, Jones, MR, Yang, X, Aben, KKH, Adank, MA, Agata, S, Andrulis, IL, Anton-Culver, H, Antonenkova, NN, Aravantinos, G, Arun, BK, Augustinsson, A, Balmaña, J, Bandera, EV, Barkardottir, RB, Barrowdale, D, Beckmann, MW, Beeghly-Fadiel, A, Benitez, J, Bermisheva, M, Bernardini, MQ, Bjorge, L, Black, A, Bogdanova, NV, Bonanni, B, Borg, A, Brenton, JD, Budzilowska, A, Butzow, R, Buys, SS, Cai, H, Caligo, MA, Campbell, I, Cannioto, R, Cassingham, H, Chang-Claude, J, Chanock, SJ, Chen, K, Chiew, YE, Chung, WK, Claes, KBM, Colonna, S, Cook, LS, Couch, FJ, Daly, MB, Dao, F, Davies, E, De La Hoya, M, De Putter, R, Dennis, J, DePersia, A, Devilee, P, Diez, O, Ding, YC, Doherty, JA, Domchek, SM, Dörk, T, Du Bois, A, Dürst, M, Eccles, DM, Eliassen, HA, Engel, C, Evans, GD, Fasching, PA, Flanagan, JM, Fortner, RT, Machackova, E, Friedman, E, Ganz, PA, Garber, J, Gensini, F, Giles, GG, Glendon, G, Godwin, AK, Goodman, MT, Greene, MH, Gronwald, J, Hahnen, E, Haiman, CA, Håkansson, N, Hamann, U, Hansen, TVO, Harris, HR, Hartman, M, Heitz, F, Hildebrandt, MAT, Høgdall, E, Høgdall, CK, Hopper, JL, Huang, RY, Huff, C, Hulick, PJ, Huntsman, DG, Imyanitov, EN, Van Der Hout, AH, Isaacs, C, Jakubowska, A, James, PA, Dareng, EO [0000-0003-0802-419X], Tyrer, JP [0000-0003-3724-4757], Barnes, DR [0000-0002-3781-7570], Yang, X [0000-0003-0037-3790], Andrulis, IL [0000-0002-4226-6435], Augustinsson, A [0000-0003-3415-0536], Barrowdale, D [0000-0003-1661-3939], Bonanni, B [0000-0003-3589-2128], Brenton, JD [0000-0002-5738-6683], Butzow, R [0000-0003-4366-5099], Chanock, SJ [0000-0002-2324-3393], Claes, KBM [0000-0003-0841-7372], de la Hoya, M [0000-0002-8113-1410], de Putter, R [0000-0001-9410-8941], Dennis, J [0000-0003-4591-1214], Devilee, P [0000-0002-8023-2009], du Bois, A [0000-0002-8477-506X], Machackova, E [0000-0002-0246-1471], Giles, GG [0000-0003-4946-9099], Godwin, AK [0000-0002-3987-9580], Greene, MH [0000-0003-1852-9239], Heitz, F [0000-0002-2412-0352], Hulick, PJ [0000-0001-8397-4078], Jakubowska, A [0000-0002-5650-0501], James, PA [0000-0002-4361-4657], and Apollo - University of Cambridge Repository

Subjects
Rare Diseases, FOS: Biological sciences, Prevention, Genetics, 32 Biomedical and Clinical Sciences, 3211 Oncology and Carcinogenesis, 3105 Genetics, 31 Biological Sciences, Ovarian Cancer, Cancer
Abstract

Funder: Funding details are provided in the Supplementary Material, Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally-efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, “select and shrink for summary statistics” (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestry; 7,669 women of East Asian ancestry; 1,072 women of African ancestry, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestry. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38(95%CI:1.28–1.48,AUC:0.588) per unit standard deviation, in women of European ancestry; 1.14(95%CI:1.08–1.19,AUC:0.538) in women of East Asian ancestry; 1.38(95%CI:1.21-1.58,AUC:0.593) in women of African ancestry; hazard ratios of 1.37(95%CI:1.30–1.44,AUC:0.592) in BRCA1 pathogenic variant carriers and 1.51(95%CI:1.36-1.67,AUC:0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.

Published
2022
Full Text
View/download PDF

39. Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database

Author

Bossart, M., primary, Plett, H., additional, Krämer, B., additional, Braicu, E., additional, Czogalla, B., additional, Klar, M., additional, Singer, S., additional, Mayr, D., additional, Staebler, A., additional, du Bois, A., additional, Kommoss, S., additional, Link, T., additional, Burges, A., additional, Heitz, F., additional, Grube, M., additional, Trillsch, F., additional, Harter, P., additional, Wimberger, P., additional, Buderath, P., additional, and Hasenburg, A., additional

Published
2022
Full Text
View/download PDF

40. LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)

Author

Kurtz, J.E., primary, Pujade-Lauraine, E., additional, Oaknin, A., additional, Belin, L., additional, Tsibulak, I., additional, Cibula, D., additional, Vergote, I.B., additional, Rosengarten, O.S., additional, Rodrigues, M.J., additional, de Gregorio, N., additional, Martinez-Garcia, J., additional, Pautier, P., additional, Mouret Reynier, M.A., additional, Selle, F., additional, D'Hondt, V., additional, Lobbedez, F. Joly, additional, Boissier, E. Bultot, additional, Floquet, A., additional, Heudel, P-E., additional, and Heitz, F., additional

Published
2022
Full Text
View/download PDF

41. 533P Real-world data of treatment and outcome of patients with relapsed ovarian cancer (OC) in Germany (QS ovar of the AGO study group)

Author

Harter, P., primary, du Bois, A., additional, Hilpert, F., additional, Kerkmann, M., additional, Sehouli, J., additional, Mahner, S., additional, de Gregorio, N., additional, Hanker, L., additional, Heitz, F., additional, Marmé, F., additional, Woelber, L., additional, Holtmann, L., additional, Elser, G., additional, and Pfisterer, J., additional

Published
2022
Full Text
View/download PDF

47. 241 Impact of co-medication on survival in patients with ovarian cancer – A analysis of 4 prospective trials of the AGO-OVAR and ENGOT/GCIG collaborators

Author

Denschlag, D, primary, Heitz, F, additional, Pfisterer, J, additional, Tutschkow, D, additional, Meier, W, additional, Harter, P, additional, Wimberger, P, additional, Mirza, MR, additional, Ray-Coquard, I, additional, Scambia, G, additional, Kim, JW, additional, Colombo, N, additional, Oaknin, A, additional, Sehouli, J, additional, Lindemann, K, additional, Floquet, A, additional, Eichbaum, M, additional, Spiegelberg, S, additional, Woopen, H, additional, and Du Bois, A, additional

Published
2021
Full Text
View/download PDF

48. 782 Survival in advanced-stage ovarian carcinoma with high VEGF-A expression after addition of bevacizumab. Results from the German ICON7 patient cohort

Author

Kommoss, S, primary, Heitz, F, additional, Serna-Higuita, L, additional, Park-Simon, TW, additional, Belau, A, additional, Hanker, L, additional, Kimmig, KR, additional, De Gregorio, N, additional, Schmalfeldt, B, additional, Baumann, K, additional, Schroeder, W, additional, Canzler, U, additional, Sehouli, J, additional, Burges, A, additional, Hilpert, F, additional, Martus, P, additional, Reuß, A, additional, Mahner, S, additional, Harter, P, additional, and Pfisterer, J, additional

Published
2021
Full Text
View/download PDF

49. 186 Surgical outcome as prognostic factor in different histologic subtypes of ovarian carcinoma- analysis of 7 phase III trials by AGO Studygroup + ENGOT

Author

Heitz, F, primary, Du Bois, A, additional, Reuß, A, additional, Pujade-Lauraine, E, additional, Mirza, MR, additional, Greggi, S, additional, Colombo, N, additional, Marth, C, additional, Vergote, IB, additional, Harter, P, additional, Ray-Coquard, I, additional, Kristensen, GB, additional, Mahner, S, additional, Hardy, AC, additional, Sehouli, J, additional, Wimberger, P, additional, Eichbaum, M, additional, Elser, G, additional, Meier, W, additional, and Pfisterer, J, additional

Published
2021
Full Text
View/download PDF

50. 786 Fertility-sparing and minimally invasive surgery in patients with stage I malignant ovarian germ cell tumours in Germany

Author

Klar, M, primary, Plett, H, additional, Harter, P, additional, Heitz, F, additional, Kommoss, S, additional, Keul, J, additional, Roser, E, additional, Sehouli, J, additional, Ioana Braicu, E, additional, Bossart, M, additional, Hasanov, MF, additional, Czogalla, B, additional, Burges, A, additional, Link, T, additional, Doris, M, additional, Staebler, A, additional, Hanker, L, additional, and Hasenburg, A, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results